Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain. METHODS: of body-surface area) plus at least one other cardiovascular risk factor. Participants were randomly assigned in a 1:1:1 ratio to receive weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg or placebo. Randomization was stratified according to use of sodium-glucose cotransporter 2 inhibitors. The primary outcome was the first major adverse cardiovascular event (MACE; a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or undetermined causes). RESULTS: A total of 4076 participants were enrolled; 2717 were assigned to receive efpeglenatide and 1359 to receive placebo. During a median follow-up of 1.81 years, an incident MACE occurred in 189 participants (7.0%) assigned to receive efpeglenatide (3.9 events per 100 person-years) and 125 participants (9.2%) assigned to receive placebo (5.3 events per 100 person-years) (hazard ratio, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P<0.001 for noninferiority; P = 0.007 for superiority). A composite renal outcome event (a decrease in kidney function or macroalbuminuria) occurred in 353 participants (13.0%) assigned to receive efpeglenatide and in 250 participants (18.4%) assigned to receive placebo (hazard ratio, 0.68; 95% CI, 0.57 to 0.79; P<0.001). Diarrhea, constipation, nausea, vomiting, or bloating occurred more frequently with efpeglenatide than with placebo. CONCLUSIONS: In this trial involving participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg than among those who received placebo. (Funded by Sanofi; AMPLITUDE-O ClinicalTrials.gov number, NCT03496298.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effects of semaglutide on albuminuria and eGFR observed in the present STEP analysis are consistent with post hoc analyses of other GLP-1RA clinical trials.”
From Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials (2023) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most GLP-1 RAs had a neutral effect on risk of HF hospitalization in the placebo-controlled RCTs assessing CV safety of glucose-lowering medications in patients with T2DM with or at high risk of ASCVD, despite increasing heart rate by 3-5 b.p.m. 70,72,158- 163,544”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging data suggest that use of both classes of drugs will provide an additive cardiovascular and kidney outcomes benefit;”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [270]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over a median follow-up of 1.8 years, efpeglenatide therapy reduced the risk of incident major adverse cardiovascular events by 27% and of a composite renal outcome event by 32%.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [214]
The cited source says what the claim attributes to it.
In the citing paper
“Some GLP-1RAs [albiglutide, efpeglenatide, dulaglutide, liraglutide and once-weekly (OW) semaglutide] reduce the risk of major adverse CV events (MACE) in people with T2D with established CVD or at high risk of CVD [6][7][8][9][10].”
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Self-citationType 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Shah, A. D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C. P., Deanfield, J., Smeeth, L., Timmis, A., & Hemingway, H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70219-0 · Cited by 1,225
Association of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965
Matsushita, K., Coresh, J., Sang, Y., Chalmers, J., Fox, C., Guallar, E., Jafar, T., Jassal, S. K., Landman, G. W. D., Muntner, P., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00040-6 · Cited by 903
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Self-citationLaiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Cited by
Items 401–500 of 873
Sinclair, M. R., Ardehali, M. M., Diamantidis, C. J., & Corsino, L. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1412874 · Cited by 10
Gul, U., Aung, T., Martin, M., Farrukh, D. N., Shah, P., Lovely, Z. S., León, E. M., Alansaari, M., Maini, S., Fariduddin, M. M., et al. (2024) · Cureus · doi:10.7759/cureus.76519 · Cited by 16
Narayan, N., Vadde, T., Sandesara, M. P., Divity, S., Mamytova, A., & Tagaev, T. (2025) · Cureus · doi:10.7759/cureus.77089 · Cited by 11
Gera, A., Latif, F., Borra, V., Naz, S., Mittal, V., Ayoobkhan, F. S., Kumar, T., Wajid, Z., Deb, N., Prasad, T., et al. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101638 · Cited by 19
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicoechea, M., et al. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.04.005 · Cited by 18
Liu, F., & Cai, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1583267 · Cited by 10
Tsuriya, D., Kobayashi, K., Takeshita, K., Hashimoto, T., Kimura, M., Muta, Y., Yokomizo, H., Takashi, Y., Tsukamoto, S., Tamura, K., et al. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70066 · Cited by 11
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 12
Rossing, P. R., Caramori, M. L., Chan, J. C. N., & Al., E. (2023) · KIDNEYS · doi:10.22141/2307-1257.11.4.2022.386 · Cited by 10
Guo, X., Sang, C., Tang, R., Jiang, C., Li, S., Liu, N., Long, D., Du, X., Dong, J., & Ma, C. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15043 · Cited by 10
Comprehensive Care of Lower-Extremity Wounds
Learned, A., Robinson, S.-A., & Nguyen, T. (2023) · Surgical Clinics of North America · doi:10.1016/j.suc.2023.04.015 · Cited by 10
Hirsh, B. J., Hirsch, J. S., Hmoud, H., Weintraub, S. F., Cha, A., LESSER, M. L., Huang, X., Xie, Y., Nahrwold, R., Joshua, J., et al. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100608 · Cited by 10
Novel pharmacological interventions for diabetic kidney disease
Tan, S. K., Pinzón-Cortés, J. A., & Cooper, M. E. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000935 · Cited by 10
Rivera, F. B., Bantayan, N. R. B., Aparece, J. P., Cruz, L. L. A., Magallong, J. V., Pine, P. L. S., Idian, A. M. N., Lumbang, G. N. O., Lerma, E. V., Lara-Breitinger, K. M., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.03.011 · Cited by 10
Tye, S. C., de Vries, S. T., Mann, J. F. E., Schechter, M., Mosenzon, O., Denig, P., & Heerspink, H. J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.786767 · Cited by 10
Kuang, Z., Hou, N., Kan, C., Han, F., Qiu, H., & Sun, X. (2022) · International Urology and Nephrology · doi:10.1007/s11255-022-03355-6 · Cited by 10
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00479-1 · Cited by 9
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9
“The primary cardiovascular benefit of GLP-1RA in people with T2D has been extensively investigated in numerous clinical trials, including ELIXA, LEADER, SUSTAIN-6, EXSCEL, REWIND, and AMPLITUDE-O [143–148].”
Gullaksen, S., Vernstrøm, L., Sørensen, S. S., Funck, K. L., Petersen, L., Bek, T., Poulsen, P. L., & Laugesen, E. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109039 · Cited by 9
Santos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 11
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 11
Lin, R., Hsu, C., Shih, M., Chien, K., & Wu, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70224 · Cited by 13
Abdelhamid, M., Abdrabou, M. M., Faris, E., Elkaffas, S. M. H., Hosny, M., & Hassan, A. (2025) · Cardiac failure review · doi:10.15420/cfr.2025.17 · Cited by 12
Anderson, J. E., Gavin, J. R., Kruger, D. F., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0020 · Cited by 10
Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
Vieira, I. H., Carvalho, T., Saraiva, J. C., Gomes, L., & Paiva, I. (2024) · Biomedicines · doi:10.3390/biomedicines12051102 · Cited by 9
RECAP study group, Tsukamoto, S., Kobayashi, K., Toyoda, M., Tone, A., Kawanami, D., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15652 · Cited by 11
Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review
Nikolaidou, A., Ventoulis, I., Karakoulidis, G., Anastasiou, V., Daios, S., Papadopoulos, S.-F., Didagelos, M., Parissis, J., Karamitsos, T. D., Kotsa, K., et al. (2024) · Medicina · doi:10.3390/medicina60060912 · Cited by 10
Gao, R., Li, Y., Li, A., Zhou, P., Zong, H., & Li, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1502050 · Cited by 10
Chalmoukou, K., Polyzos, D., Manta, E., Tatakis, F., Konstantinidis, D., Thomopoulos, C., & Costas, T. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.12.018 · Cited by 10
Ghosal, S., & Sinha, B. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109824 · Cited by 9
Seetaloo, N., & Phillips, J. J. (2022) · Journal of Visualized Experiments · doi:10.3791/64050 · Cited by 9
Sacre, J. W., Magliano, D. J., & Shaw, J. E. (2022) · Diabetes Care · doi:10.2337/dc21-1929 · Cited by 9
Progress in the management of patients with diabetes and chronic kidney disease
Garcia, L. P., Thomas, S. S., Rajesh, H., & Navaneethan, S. D. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000811 · Cited by 10
Kobayashi, K., Toyoda, M., Tone, A., Kawanami, D., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., Takeda, H., Yokomizo, H., et al. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641231222837 · Cited by 10
Brockmeyer, M., Parco, C., Vargas, K. G., Westenfeld, R., Jung, C., Kelm, M., Roden, M., Akbulut, C., Schlesinger, S., Wolff, G., et al. (2024) · Journal of Nephrology · doi:10.1007/s40620-023-01858-8 · Cited by 9
Recent advances in the pharmacotherapeutic management of diabetic kidney disease
Block, T. J., Batu, D., & Cooper, M. E. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2054699 · Cited by 10
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
Tirandi, A., Montecucco, F., Carbone, F., & Liberale, L. (2024) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16658 · Cited by 8
Connolly, D. L., Collins, E., Ren, H., Ming, S. W. Y., Davidson, J. A., & Bain, S. C. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01715-w · Cited by 8
Atypical diabetic neuropathies
McCray, B. A., Stino, A. M., Davalos, L., Quigley, S., Becker, B., & Callaghan, B. C. (2025) · BMJ · doi:10.1136/bmj-2024-081109 · Cited by 10
Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review
Tuttle, K. R., Ji, L., Mathieu, C., & Rosen, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70180 · Cited by 8
Zhang, J., Guan, X., Kong, M.-W., Xia, M., Yu, Y., & Zhang, C. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156433 · Cited by 9
Lin, P., Zeng, B., Hsu, C., Suen, M., Hung, C., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · Biomolecules · doi:10.3390/biom15111622 · Cited by 8
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
GLP-1 Receptor Agonists for Cardiovascular Protection: A Matter of Time
Caruso, I., Cignarelli, A., Laviola, L., & Giorgino, F. (2022) · Diabetes Care · doi:10.2337/dc21-1839 · Cited by 8
Deo, S. V., Marsia, S., McAllister, D., Elgudin, Y. E., Sattar, N. A., & Pell, J. P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14738 · Cited by 9
Self-citationBernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 9
Sabina, M., & Alsamman, M. (2024) · Cardiology Research · doi:10.14740/cr1600 · Cited by 10
Zhu, J., Wilding, J. P. H., & Gu, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i10.2135 · Cited by 9
Triglyceride glucose index as a biomarker for heart failure risk in H-type hypertension patients
Xu, Z., Yan, X., Li, D., & Huang, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-89211-w · Cited by 11
Morales, E., Martin, W. P., Bevc, S., Jenssen, T. G., Miglinas, M., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf069 · Cited by 8
Practical application of semaglutide: From evidence-based research to expert decisions
Салухов, В. В., Galstyan, G. R., Khalimov, Y. S., Бакулин, И. Г., Cherkashin, D. V., Shadrichev, F. E., & Sukhotskaia, N. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-185 · Cited by 8
Schechter, M., Fischer, M., & Mosenzon, O. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14675 · Cited by 8
Cheng, J. W. M., Colucci, V. J., Kalus, J. S., & Spinler, S. A. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231154021 · Cited by 8
Cobo, A. L., Masson, W. M., Lobo, M., Barbagelata, L., Forte, E. H., Corral, P., & Nogueira, J. P. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101940 · Cited by 8
Diévart, F., Darmon, P., Halimi, J., Hadjadj, S., Angoulvant, D., Prévost, G., Delanaye, P., & Boivin, J. (2023) · Néphrologie & Thérapeutique · doi:10.1684/ndt.2023.25 · Cited by 12
Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases
Behrooz, L., Lenneman, C. G., & Hamburg, N. M. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01961-z · Cited by 9
A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
Selvarajan, R., & Subramanian, R. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s385196 · Cited by 8
Glucagon‐like peptide 1 receptor agonists in heart failure: the need for a rewind
Ferreira, J. P., & Neves, J. S. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2693 · Cited by 8
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Palani, A., Patel, S., Patel, S., Srivastava, S., Patel, J., Salehin, S., Birnbaum, Y., & Allencherril, J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07744-8 · Cited by 8
Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review
Zhang, H., Chen, J., Wang, N., Chen, W., Xu, Y., & Gui, D. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70077 · Cited by 9
Zeng, H., Hu, J., Yang, Z., Wang, M., Gao, L., Tang, Z., Zhang, J., Yin, P., Gu, J., & Wang, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-17574-1 · Cited by 10
Bonfioli, G. B., Pagnesi, M., Tomasoni, D., Rakisheva, A., & Metra, M. (2025) · Cardiac failure review · doi:10.15420/cfr.2025.10 · Cited by 11
Contemporary management of advanced chronic kidney disease: An evidence-based review
Baker, L. W., Ovincy, C., Souvalian, L., Hickson, L. J., & Chebib, F. T. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106557 · Cited by 9
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Meier, M., Cummings, J. L., Abdelsaid, M. A., Feliciano, J., Eusebe, J., Stirn, H., & Coucha, M. M. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101282 · Cited by 7
Wali, A. F., Rangraze, I. R., Khan, S. S., Mufti, U., El‐Tanani, M., & Rizzo, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736380 · Cited by 7
Xu, Y., Huang, T., Zhang, Y., Ji, D., Tuttle, K. R., Carrero, J. J., & Fu, E. L. (2026) · Circulation · doi:10.1161/circulationaha.125.075157 · Cited by 7
Wang, D., Mo, Y., Tan, X., Xie, J.-Y., Wang, H., & Wen, F. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02289-y · Cited by 7
Garagoli, F., Masson, W. M., Barbagelata, L., & Lobo, M. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endinu.2025.501562 · Cited by 13
Leening, M. J. G., & Mahmoud, K. D. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00820-x · Cited by 7
SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
Qiu, M., Xu-bin, W., & Wei, W. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.791311 · Cited by 7
Li, L., Wang, S., Huang, G., & You, J. (2022) · Medicine · doi:10.1097/md.0000000000030693 · Cited by 7
Ghosal, S., & Sinha, B. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01359-0 · Cited by 7
Shakour, N., Hoseinpoor, S., Rajabian, F., Azimi, S. G., Iranshahi, M., Sadeghi‐Aliabadi, H., & Hadizadeh, F. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2298734 · Cited by 8
Gilbert, M. P., Skelly, J. M., Hernandez, A. F., Green, J. B., Krychtiuk, K. A., Granger, C. B., Leiter, L. A., McMurray, J. J. V., Prato, S. D., & Pratley, R. E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15479 · Cited by 7
Self-citationBramlage, P., Vijayan, A., Varghese, T. P., Sadanandan, D. M., Lanzinger, S., & Rodriguez, C. F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70010 · Cited by 7
Type 2 diabetes mediated heart failure: focus on early recognition and clinical strategies
Chen, X., Li, W. S., Zheng, J.-W., Huang, M., Wang, J., & Wu, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630686 · Cited by 6
Lin, Z., Li, Z., & Jia, Q. (2025) · Journal of Stroke · doi:10.5853/jos.2025.00584 · Cited by 6
Salerno, E., Fumarulo, I., Garramone, B., Vaccarella, M., Ierardi, C., Burzotta, F., & Aspromonte, N. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103213 · Cited by 6
Ahmed, A. A. O., Ahmed, O., Ahmed, R. A. O., Ahmed, R. A. O., Mohammed, M. A. E. A., Ahmed, Y., Abbas, M., Ibrahim, M. A. A., Abakar, M. E. M., Dahab, K. E. M., et al. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05455-4 · Cited by 8
Chen, J.-J., Hsu, C., Hung, C., Suen, M.-W., Wang, H.-Y., Yang, W.-C., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020608 · Cited by 7
Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
Trivedi, K., & Dolinsky, V. W. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0163 · Cited by 7
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Birker, S., Meier, J. J., & Nauck, M. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-25296-x · Cited by 6
Alsheikh, A., Al-Jedai, A. H., Almudaiheem, H., Alaidarous, S. B., Alshehri, A., Elbadawi, H., Alghamdi, S., Aljehani, F., Alobaidi, S. A., Altuwaijri, T. A., et al. (2025) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2025.161004 · Cited by 6
Li, J., Tian, Y., Li, L., Zhao, Y., Yang, S., Xu, W., Zhu, D., Ye, J., Chen, J., Liu, W.-T., et al. (2025) · MedComm · doi:10.1002/mco2.70094 · Cited by 6
Trenas, A., Velasco, M. Á. P., Bernal-López, M. R., Lopez-Carmona, M. D., Gómez‐Doblas, J. J., Martínez-Esteban, M. D., Bouarich, O., García‐Casares, N., Fernández‐García, D., de Lucas, M.-D. G., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.007 · Cited by 6
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
Aoyama, K., Okada, A., Kaneko, H., Azegami, T., Suzuki, Y., Meguro, S., Fujiu, K., Takeda, N., Morita, H., Node, K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70255 · Cited by 6
Yarlagadda, C., Abutineh, M., Reddy, A. J., Landau, A. B., Travis, L. M., Perrone, C. G., Idriss, A., & Patel, R. P. (2023) · Cureus · doi:10.7759/cureus.36438 · Cited by 7
Gerstein, H. C., Mian, R. I., Ramasundarahettige, C. F., Branch, K. R., Prato, S. D., Lam, C. S. P., Lópes, R. D., Pratley, R. E., Rosenstock, J., & Sattar, N. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15417 · Cited by 6
Self-citationRico-Fontalvo, J. E., Reina, M., Soler, M. J., Unigarro-Palacios, M., Castañeda-González, J. P., Quintero, J. J., Raad-Sarabia, M., de Moraes, T. P., & Daza-Arnedo, R. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2024-0101en · Cited by 7
Type 2 diabetes, heart failure and the treatment of their comorbidity
Wang, S., & Li, S. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09264-4 · Cited by 6
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 11
Zhang, S., Zong, Y., Hu, Y., Sheng, Y., & Xiao, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1146798 · Cited by 7
Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. Reply.
Gerstein, H. C., & Khurmi, N. S. (2021) · PubMed · doi:10.1056/nejmc2115776 · Cited by 3
Cardiovascular-kidney-metabolic syndrome and treatment advances: a narrative review
Peña, C., Flores, J., & NUGENT, K. M. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09607-7 · Cited by 6
Li, W., Liang, X., Sun, N., & Zhang, D. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01948-7 · Cited by 5
Metadata
- Authors
- Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., Dyal, L., & Branch, K.
- Affiliations
- University of Pisa (IT)
- From the Population Health Research Institute, Hamilton Health Sciences (H.C.G., C.R., L.H., L.D.), and McMaster University (H.C.G.) — both in Hamilton, ON, Canada; the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (N.S.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); AdventHealth Translational Research Institute, Orlando, FL (R.P.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.); National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); Sanofi, Bridgewater, NJ (N.S.K.); the Section of Metabolic Diseases and Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy (S.D.P.); and the Division of Cardiology, University of Washington, Seattle (K.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-02
- Volume
- 385
- Issue
- 10
- Pages
- 896-907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177365549
- Cited by
- 829
- References
- 29
- Citations by year
- 2026: 150 · 2025: 187 · 2024: 159 · 2023: 149 · 2022: 136 · 2021: 47
- FWCI
- 91.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- efpeglenatide, type 2 diabetes, GLP-1 receptor agonists, exendin-4, major adverse cardiovascular events, cardiovascular risk, renal outcomes, renal function decline, macroalbuminuria, SGLT2 inhibitors, gastrointestinal adverse effects, non-inferiority, cardiovascular disease history, kidney disease, cardiovascular risk factors, myocardial infarction
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Kidney Diseases, Male, Middle Aged, Proline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
